Comparison of Current International Guidelines for the Management of Dyslipidemia
- PMID: 36498823
- PMCID: PMC9737468
- DOI: 10.3390/jcm11237249
Comparison of Current International Guidelines for the Management of Dyslipidemia
Abstract
The dyslipidemia guidelines of the three major societies have been revised recently in light of new evidence. LDL-C is the primary target in the ESC, AHA/ACC/Multisociety and Canadian Cardiovascular Society (CCS) guidelines. These guidelines uniformly recommend intensifying lipid-lowering treatment with increased risk; however, the risk estimation systems are different across the guidelines. The ESC guidelines have LDL-C goals which have become more stringent over the years and advocate the use of statin and, if necessary, non-statin therapies to obtain these goals. AHA/ACC/Multisociety guidelines have LDL-C thresholds and advocate combination therapy less liberally and for selected patients. All three guidelines acknowledge the importance of shared decision making. Despite some divergent approaches and recommendations, the main principles and messages are the same across the guidelines. To combat the epidemic of cardiovascular disease, our focus should be not on the differences but on implementing the guidelines in our region.
Keywords: dyslipidemia; primary prevention; risk management; secondary prevention.
Conflict of interest statement
Aygun have no confict or competing interest relevant to this manuscript. Tokgozoglu reports participation in a Speaker/Advisory Board for Abbott, Amgen, Astra Zeneca, Bayer, Daiichi-Sankyo, Janssen, Mylan, Novartis, Novo Nordisk, Pfizer, Recordati, Sanofi, Servier and she reports being the Past President of the European Atherosclerosis Society and the Past President of the Turkish Society of Cardiology.
References
-
- Parini P., Frikke-Schmidt R., Tselepis A.D., Moulin P., von Eckardstein A., Binder C.J., Catapano A.L., Ray K.K., Tokgözoğlu L. Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe. Atherosclerosis. 2021;322:77–81. doi: 10.1016/j.atherosclerosis.2021.02.007. - DOI - PubMed
-
- Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtcher K.K., Blumenthal R.S., Braun L.T., De Ferranti S., Faiella-Tommasino J., Forman D.E., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart association task force on clinical practice guidelines. Circulation. 2019;139:e1082–e1143. - PMC - PubMed
-
- Visseren F.L., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Bäck M., Benetos A., Biffi A., Boavida J.M., Capodanno D., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC) Eur. Heart J. 2021;42:3227–3337. - PubMed
-
- Pearson G.J., Thanassoulis G., Anderson T.J., Barry A.R., Couture P., Dayan N., Francis G.A., Genest J., Grégoire J., Grover S.A., et al. Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can. J. Cardiol. 2021;37:1129–1150. doi: 10.1016/j.cjca.2021.03.016. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources